ArticleTranslational andrology and urology2025
SChLAP1 regulates the metastasis and apoptosis of prostate cancer partly via miR-101.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation.Cancers · 2026Review
- Microbiota-miR-101 interactions in obesity-associated colorectal cancer: from barrier dysfunction to precision therapeutic strategies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PC) remains one of the leading causes of cancer-related mortality, necessitating further research into novel prognostic biomarkers and therapeutic targets. Long noncoding RNA second chromosome locus-associated with prostate-1 (SChLAP1) plays a crucial role in the aggressiveness of PC; however, its precise mechanism remains unclear. This study aimed to investigate the role of SChLAP1 in PC metastasis and apoptosis, with a particular focus on its interaction with miR-101. Methods: The expression levels of SChLAP1 were analyzed by quantitative polymerase chain reaction (qPCR) and fluorescence in situ hybridization (FISH) in 42 clinical specimens, including 21 PC tissues and their corresponding adjacent normal tissues, as well as in PC cell lines (PC-3, DU145, and LNCaP). Functional assays were performed using lentivirus-mediated knockdown and overexpression of SChLAP1 and miR-101-5p. Cell proliferation, invasion, apoptosis, and autophagy were assessed via Cell Counting Kit-8 assays, Transwell migration assays, flow cytometry, and Western blot analysis. Bioinformatics analysis and complementary expression experiments were used to validate the interaction between SChLAP1 and miR-101-5p. An Results: SChLAP1 was significantly upregulated in PC tissues and was correlated with higher Gleason scores (P<0.05). Knockdown of SChLAP1 suppressed PC-3 cell proliferation, invasion, and cell cycle progression while promoting apoptosis through MMP-9/Bcl-2 downregulation and caspase-3 activation. SChLAP1 functioned as a cytoplasmic competing endogenous RNA (ceRNA) by directly binding to miR-101-5p. Overexpression of miR-101-5p inhibited metastasis and induced apoptosis but had no significant effect on autophagy. Conclusions: SChLAP1 promotes PC progression by regulating metastasis and apoptosis via the miR-101-5p axis. The SChLAP1/miR-101-5p signaling pathway represents a novel diagnostic and therapeutic target, with potential implications for improving prognostic assessment and treatment strategies for advanced PC. Further clinical studies are warranted to evaluate its therapeutic potential in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.